Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (2 issues)
Up 2.63% in a sixth straight advance to a year-to-date high, RSI at 74.6 and RSI(7) at 83.5 overbought after a 20.1% month; interim net profit grew 627.1% with guidance raised, so the fundamentals are sound — but 15 analysts leave only 19.3% of upside at an extended level — wait for a pullback.
Up 5.26% with the biopharma complex, RSI overbought at 69.6, above the 50-day at HK$179.25 and 200-day at HK$188.40; sector beta without a company-specific catalyst. Sidelines.